Total Payments
$9,661
2024 Payments
$23.68
Companies
59
Transactions
472
Medicare Patients
568
Medicare Billing
$92,248
Payment Breakdown by Category
Food & Beverage$8,583 (88.8%)
Education$1,078 (11.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,583 | 448 | 88.8% |
| Education | $1,078 | 24 | 11.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $856.83 | 47 | $0 (2020) |
| PFIZER INC. | $852.92 | 50 | $0 (2022) |
| Amgen Inc. | $824.84 | 28 | $0 (2020) |
| Incyte Corporation | $689.30 | 17 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $624.99 | 59 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $597.89 | 37 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $410.27 | 11 | $0 (2020) |
| Celgene Corporation | $389.11 | 18 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $319.77 | 19 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $272.59 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23.68 | 1 | Boston Scientific Corporation ($23.68) |
| 2023 | $63.67 | 3 | Pharmacyclics LLC, An AbbVie Company ($22.66) |
| 2022 | $340.17 | 7 | AVEO Pharmaceuticals, Inc. ($138.59) |
| 2021 | $218.65 | 7 | Incyte Corporation ($122.14) |
| 2020 | $1,326 | 55 | Amgen Inc. ($233.61) |
| 2019 | $3,875 | 182 | PFIZER INC. ($446.44) |
| 2018 | $2,496 | 141 | Novartis Pharmaceuticals Corporation ($387.02) |
| 2017 | $1,318 | 76 | E.R. Squibb & Sons, L.L.C. ($191.74) |
All Payment Transactions
472 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 10/19/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
| 05/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.10 | General |
| Category: Hematology | ||||||
| 08/09/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2022 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $12.00 | General |
| Category: ONCOLOGY | ||||||
| 07/28/2022 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $119.61 | General |
| Category: Oncology | ||||||
| 06/10/2022 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $138.59 | General |
| Category: Oncology | ||||||
| 05/25/2022 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $17.77 | General |
| Category: ONCOLOGY | ||||||
| 01/14/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 01/07/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $25.52 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2021 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2021 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2021 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Education | In-kind items and services | $20.91 | General |
| Category: Prostate Cancer | ||||||
| 10/13/2021 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/11/2021 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $122.14 | General |
| Category: Oncology | ||||||
| 11/10/2020 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: BioOncology | ||||||
| 11/10/2020 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.16 | General |
| Category: ONCOLOGY | ||||||
| 07/07/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $22.07 | General |
| Category: Oncology | ||||||
| 06/12/2020 | PFIZER INC. | BOSULIF (Drug), DAURISMO, RUXIENCE | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/19/2020 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: Oncology | ||||||
| 05/14/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 05/13/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 94 | 279 | $107,245 | $20,244 |
| 2022 | 6 | 169 | 431 | $171,305 | $33,128 |
| 2021 | 6 | 167 | 361 | $106,230 | $29,133 |
| 2020 | 6 | 138 | 274 | $33,244 | $9,743 |
Total Patients
568
Total Services
1,345
Medicare Billing
$92,248
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 191 | $76,400 | $14,492 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 20 | $10,700 | $2,205 | 20.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $8,250 | $1,535 | 18.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 21 | $5,775 | $1,120 | 19.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 11 | 36 | $6,120 | $891.00 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 87 | 298 | $119,200 | $23,257 | 19.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $13,500 | $2,686 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 23 | $12,305 | $2,652 | 21.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 19 | 36 | $9,900 | $1,898 | 19.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $9,600 | $1,476 | 15.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 14 | 40 | $6,800 | $1,159 | 17.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 47 | 146 | $24,820 | $8,975 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 100 | $40,000 | $8,344 | 20.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 53 | $13,250 | $4,683 | 35.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 20 | $10,700 | $2,418 | 22.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $11,250 | $2,392 | 21.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 25 | 27 | $6,210 | $2,321 | 37.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 48 | 87 | $24,039 | $6,357 | 26.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 18 | $4,475 | $1,643 | 36.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 12 | $2,160 | $757.21 | 35.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2020 | 21 | 40 | $920.00 | $415.47 | 45.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 23 | 48 | $960.00 | $366.56 | 38.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 24 | 69 | $690.00 | $203.82 | 29.5% |
About Joomee Shim
Joomee Shim is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/15/2010. The National Provider Identifier (NPI) number assigned to this provider is 1942526934.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Joomee Shim has received a total of $9,661 in payments from pharmaceutical and medical device companies, with $23.68 received in 2024. These payments were reported across 472 transactions from 59 companies. The most common payment nature is "Food and Beverage" ($8,583).
As a Medicare-enrolled provider, Shim has provided services to 568 Medicare beneficiaries, totaling 1,345 services with total Medicare billing of $92,248. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Los Angeles, CA
- Active Since 04/15/2010
- Last Updated 11/27/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942526934
Products in Payments
- KEYTRUDA (Biological) $582.46
- OPDIVO (Biological) $476.90
- XTANDI (Drug) $343.51
- NINLARO (Drug) $343.21
- Revlimid (Drug) $238.96
- Imbruvica (Drug) $236.78
- JAKAFI (Drug) $224.27
- BAVENCIO (Drug) $184.25
- IMFINZI (Drug) $162.42
- RYDAPT (Drug) $161.82
- Venclexta (Drug) $159.20
- MEKINIST (Drug) $156.13
- Lenvima (Drug) $154.31
- GILOTRIF (Drug) $145.29
- PROMACTA (Drug) $143.14
- FOTIVDA (Drug) $138.59
- Kyprolis (Biological) $137.75
- DARZALEX (Biological) $133.96
- INLYTA (Drug) $130.05
- SOLIRIS (Drug) $122.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
George Yaghmour
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334